J.P. Morgan is out with its report today on Vertex Pharmaceuticals VRTX, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "Reiterate Neutral Rating. While we have high expectations for VX-770 in the STRIVE trial, this is not enough to change our thesis on Vertex, particularly, given little room for error for the telaprevir launch and longer-term competition in the HCV space."
J.P. Morgan maintains a $43 PT on VRTX.
At the time of posting, shares of VRTX were trading at $43.96, up 15.02% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHealth CareJ.P. Morganvertex pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in